HER2 Biomarker Evolving as Enhertu Shows Activity in Breast Cancers With Ultralow Expression
Premium
The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists revisiting patients' old test results.
While technology advances were perhaps less dramatic than in the year prior, several firms teased future releases that could have significant impacts.
Biobanks have been making strides in gathering data from more diverse populations this year while the evidence for the clinical utility of embryo PRS testing remains insufficient.
Oxford Nanopore Technologies Sues BGI, Affiliates for Sequencing Technology Contract Breach
Among other demands, Oxford Nanopore asked the UK court to grant an injunction to prevent the sale and licensing of BGI's nanopore sequencing products.
International Consensus Statement Says Microbiome-Based Diagnostic Tests Not Ready for Prime Time
Researchers laid out a set of ethical, organizational, and technical guidelines for the development, commercial use, and clinical implementation of microbiome tests.
MiDiagnostics Closes €30M Series D Round Led by Thermo Fisher Scientific
The Belgium-based biotech firm will use the funding to further develop its sterility test for biopharma customers, leveraging its silicon chip-based qPCR technology.